Your browser doesn't support javascript.
loading
Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy
García-Barreras, S; Rozet, F; Nunes-Silva, I; Srougi, V; Sanchez-Salas, R; Barret, E; Galiano, M; Cathelineau, X.
Afiliación
  • García-Barreras, S; Institut Mutualiste Montsouris. Department of Urology. Paris. France
  • Rozet, F; Institut Mutualiste Montsouris. Department of Urology. Paris. France
  • Nunes-Silva, I; Institut Mutualiste Montsouris. Department of Urology. Paris. France
  • Srougi, V; Institut Mutualiste Montsouris. Department of Urology. Paris. France
  • Sanchez-Salas, R; Institut Mutualiste Montsouris. Department of Urology. Paris. France
  • Barret, E; Institut Mutualiste Montsouris. Department of Urology. Paris. France
  • Galiano, M; Institut Mutualiste Montsouris. Department of Urology. Paris. France
  • Cathelineau, X; Institut Mutualiste Montsouris. Department of Urology. Paris. France
Clin. transl. oncol. (Print) ; 20(8): 1004-1010, ago. 2018. tab
Article en En | IBECS | ID: ibc-173683
Biblioteca responsable: ES1.1
Ubicación: BNCS
ABSTRACT
Purpose: To evaluate predictive factors associated with detectable prostate-specific antigen (PSA) and describe clinical recurrence (CR) and cancer-specific mortality (CSM) after robot-assisted radical prostatectomy (RARP). Methods: The study included 2500 patients who were treated with RARP at a single institution between 2000 and 2016. All patients had clinically localized PCa. Patients were divided into two groups according to PSA value at 6 weeks after surgery: undetectable (n = 2271; PSA < 0.1 ng/dl) and persistently elevated (n = 229; PSA ≥ 0.1 ng/dl). The association between various covariates and: (1) detectable PSA and (2) CR was evaluated. Kaplan-Meier analyses estimated CR and CSM rates according to PSA persistence. Results: Inside the group of detectable PSA, 146 men (63.75%) received adjuvant treatments, 44 patients (19.21%) salvages therapies and 38 men (16.5%) experienced CR. Factors associated with aggressive disease predicted PSA persistence. Within patients with detectable PSA, pathologic stage ≥ pT3a (HR 2.71; p < 0.029) and to received adjuvant androgen deprivation therapy (ADT) due to bad prognosis tumors (HR 13.36; p < 0.001) were associated with CR. Overall 14 (0.56%) died of PCa. 5 and 10-year CSM rates were higher for patients with CR (9.6 and 23.7%, p < 0.001), and Gleason ≥ 8 (5.7 and 6.9%, p = 0.003). Conclusions: A detectable PSA is affected by factors associated with aggressive prostate cancer. Within men with persistent PSA, those with higher pathologic stage and who received adjuvant ADT are more likely to have CR. Patients with CR, Gleason ≥ 8, and those who received adjuvant ADT must have a close monitoring due to the high rate of mortality
RESUMEN
No disponible
Asunto(s)
Buscar en Google
Colección: 06-national / ES Base de datos: IBECS Asunto principal: Prostatectomía / Neoplasias de la Próstata / Antígeno Prostático Específico / Procedimientos Quirúrgicos Robotizados Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2018 Tipo del documento: Article
Buscar en Google
Colección: 06-national / ES Base de datos: IBECS Asunto principal: Prostatectomía / Neoplasias de la Próstata / Antígeno Prostático Específico / Procedimientos Quirúrgicos Robotizados Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2018 Tipo del documento: Article